Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
1.960
-0.060 (-2.97%)
At close: Sep 26, 2025, 4:00 PM EDT
1.940
-0.020 (-1.02%)
After-hours: Sep 26, 2025, 7:29 PM EDT
Adagene Revenue
Adagene had revenue of $103.20K in the twelve months ending June 30, 2025, down -87.35% year-over-year. In the year 2024, Adagene had annual revenue of $103.20K, down -99.43%.
Revenue (ttm)
$103.20K
Revenue Growth
-87.35%
P/S Ratio
895.09
Revenue / Employee
$748
Employees
138
Market Cap
92.38M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ADAG News
- 11 days ago - Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - GlobeNewsWire
- 22 days ago - Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - GlobeNewsWire
- 24 days ago - Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - GlobeNewsWire
- 4 weeks ago - Adagene to Participate in Two Investor Conferences in September - GlobeNewsWire
- 6 weeks ago - Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 2 months ago - Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - GlobeNewsWire
- 2 months ago - Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate - GlobeNewsWire
- 3 months ago - Adagene announces up to $25 million strategic investment from Sanofi - GlobeNewsWire